Pfizer’s Genotropin Gains SGA Indication In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Pfizer Japan obtained Ministry of Health, Labor and Welfare approval for marketing Genotropin (somatropin) as Japan's first drug to treat small-for-gestational age, or intrauterine growth retardation, the company announced Oct. 16